Stock Market News
Abcam rises on upbeat data and boardroom buying
09-04-2014 14:48
Add To Google +1 | Tweet |
Shares in Abcam were healthier on Wednesday after an industry research group talked up its prospects and a director bought shares in the biotechnology firm worth about £50,000.
The stock had risen 22.5p or 6.4% to 373p by 15:00 in London as independent antibody search engine CiteAb said latest data showed that weaker-than-expected earnings unveiled by Abcam at the start of March were a temporary blip.
Shares in Cambridge-based Abcam, which supplies antibodies and re-agents, have dropped about 27% since it said last month that it remained cautious about US medical research funding and had faced some business disruption due to a re-organisation in China.
But CiteAb said its data showed that Abcam's share of the research antibody market had grown steadily and significantly in the last five years.
It added that China was a key research antibody growth market and Abcam was making good progress in improving its Chinese market share.
CiteAb's Dr Andrew Chalmers said: "Overall, it would certainly seem too soon to write off Abcam. This is a company going through significant change and making large investments, but all in areas where experts predict growth."
Meanwhile, Abcam said non-executive director Louise Patten had bought 13,617 shares at 367p per share, giving her a stake of about 0.01%.
On Monday, broker Canaccord Genuity downgraded its earnings estimates for Abcam in 2014 and 2015, citing the group's increased investment. But it upgraded the company to 'hold', adding: "The long-term outlook for Abcam remains intact."
PW
The stock had risen 22.5p or 6.4% to 373p by 15:00 in London as independent antibody search engine CiteAb said latest data showed that weaker-than-expected earnings unveiled by Abcam at the start of March were a temporary blip.
Shares in Cambridge-based Abcam, which supplies antibodies and re-agents, have dropped about 27% since it said last month that it remained cautious about US medical research funding and had faced some business disruption due to a re-organisation in China.
But CiteAb said its data showed that Abcam's share of the research antibody market had grown steadily and significantly in the last five years.
It added that China was a key research antibody growth market and Abcam was making good progress in improving its Chinese market share.
CiteAb's Dr Andrew Chalmers said: "Overall, it would certainly seem too soon to write off Abcam. This is a company going through significant change and making large investments, but all in areas where experts predict growth."
Meanwhile, Abcam said non-executive director Louise Patten had bought 13,617 shares at 367p per share, giving her a stake of about 0.01%.
On Monday, broker Canaccord Genuity downgraded its earnings estimates for Abcam in 2014 and 2015, citing the group's increased investment. But it upgraded the company to 'hold', adding: "The long-term outlook for Abcam remains intact."
PW
Related share prices |
---|
Abcam (ABC) share price |
Stock News is provided by Digital Look Corporate Solutions from Sharecast news. Please read the terms and conditions of useage of this data. Republication or redistribution of content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd.
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- RBS share price
- Diageo share price
- Standard Life Share Price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- Morrisons Share Price
- Aviva Share Price
- LGO Share price
- Tullow Oil Share Price
- SXX Share Price
- Easyjet Share Price
- Next Share Price
- Thomas Cook Share Price
- SSE Share Price
- IAG Share Price
- Bat share price
- Monitise Share Price
- Kingfisher share price
- Dragon Oil share price
- UKOG share price
- SOLG share price